Guardant Health (NASDAQ:GH) CEO Helmy Eltoukhy Sells 90,565 Shares

Guardant Health, Inc. (NASDAQ:GH) CEO Helmy Eltoukhy sold 90,565 shares of the company’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $103.82, for a total transaction of $9,402,458.30. Following the completion of the transaction, the chief executive officer owned 2,047,143 shares of the company’s stock, valued at approximately $212,534,386.26. This trade represents a 4.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Guardant Health Stock Performance

Shares of Guardant Health stock traded down $2.53 on Wednesday, hitting $97.47. The company’s stock had a trading volume of 1,912,147 shares, compared to its average volume of 2,452,903. The company has a market capitalization of $12.29 billion, a price-to-earnings ratio of -30.36 and a beta of 1.58. Guardant Health, Inc. has a 1 year low of $29.91 and a 1 year high of $112.43. The firm has a fifty day moving average price of $90.23 and a 200-day moving average price of $66.58.

Guardant Health (NASDAQ:GH) last announced its earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.09. The business’s quarterly revenue was up 38.5% compared to the same quarter last year. During the same period last year, the company earned ($0.88) EPS. As a group, analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Baillie Gifford & Co. raised its stake in shares of Guardant Health by 6.6% during the 3rd quarter. Baillie Gifford & Co. now owns 5,127,692 shares of the company’s stock worth $320,378,000 after buying an additional 317,906 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Guardant Health by 27.3% during the 2nd quarter. Invesco Ltd. now owns 3,558,501 shares of the company’s stock valued at $185,184,000 after acquiring an additional 763,834 shares in the last quarter. Franklin Resources Inc. lifted its position in Guardant Health by 26.1% during the 3rd quarter. Franklin Resources Inc. now owns 2,926,315 shares of the company’s stock worth $182,836,000 after acquiring an additional 606,368 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Guardant Health by 0.5% during the second quarter. Geode Capital Management LLC now owns 2,920,714 shares of the company’s stock worth $152,014,000 after buying an additional 13,088 shares in the last quarter. Finally, ARK Investment Management LLC grew its holdings in Guardant Health by 100.4% during the 2nd quarter. ARK Investment Management LLC now owns 2,823,497 shares of the company’s stock worth $146,935,000 after acquiring an additional 1,414,381 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analysts Set New Price Targets

GH has been the subject of several recent research reports. Mizuho increased their price objective on Guardant Health from $100.00 to $120.00 and gave the company an “outperform” rating in a research note on Wednesday. William Blair reissued an “outperform” rating on shares of Guardant Health in a research report on Thursday, September 25th. Leerink Partners increased their price target on Guardant Health from $115.00 to $155.00 and gave the stock an “outperform” rating in a report on Monday. Canaccord Genuity Group set a $100.00 price objective on shares of Guardant Health in a research report on Thursday, October 30th. Finally, Morgan Stanley lifted their target price on Guardant Health from $105.00 to $130.00 and gave the company an “overweight” rating in a research report on Monday, December 1st. Twenty-three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $95.52.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.